Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Zypadhera ® (olanzapin)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Further information on maintenance dose
Olanzapine LAI provides therapeutic levels of systemic olanzapine from the very first injection. However, approximately 3 months are needed to re-establish steady state.1
During treatment, dose may subsequently be adjusted on the basis of individual clinical status. After clinical reassessment, dose may be adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to 405 mg every 4 weeks (Table 1).2
Table 1. Recommended dose scheme between oral olanzapine and olanzapine pamoate2
Target oral olanzapine dose |
Recommended starting dose of olanzapine pamoate |
Maintenance dose after 2 month of olanzapine pamoate treatment |
10 mg/day |
210
mg/2 weeks |
150
mg/2 weeks |
15 mg/day |
300 mg/2 weeks |
210
mg/2 weeks |
20 mg/day |
300 mg/2 weeks |
300 mg/2 weeks |
These doses of olanzapine LAI have been shown to sustain steady-state olanzapine concentrations over 2 to 4 weeks that correspond to those maintained by an oral dose of 10 to 20 mg olanzapine administered once daily.3
Some specific patient populations may require cautious dose escalation.1 For full information please refer to the summary of product characteristics.
Pharmacokinetic background information
The half-life of olanzapine after olanzapine pamoate is 30 days compared to 30 hours following oral administration.2
During the initial three months of treatment with olanzapine pamoate, accumulation of olanzapine was observed but there was no additional accumulation during long-term use (12 months) in patients who were injected with up to 300 mg every two weeks.2
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.
3. Mitchell M, Kothare P, Bergstrom R, et al. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. Clin Ther. 2013;35(12):1890-1908. http://dx.doi.org/10.1016/j.clinthera.2013.09.023
Glossary
LAI = long-acting injection = olanzapine-pamoate
Datum fӧr senaste ӧversyn 2019 M05 01